Table 2.
Clinical trials targeting interleukin (IL)-20, IL-22, and IL-24
| Intervention | Indication | Clinical stage | Sponsor |
|---|---|---|---|
| NNC109-0012: anti-IL-20 | Rheumatoid arthritis | Phase I NCT00818064 | Novo Nordisk A/S |
| Phase I NCT01038674 | |||
| Phase II | |||
| NCT01282255 | |||
| NCT01636817 (terminated) | |||
| NCT01636843 (terminated) | |||
| Psoriasis | Phase I | ||
| NCT01261767 (terminated) | |||
| F-652: | Alcoholic hepatitis | Phase I/II NCT02655510 | Mayo Clinic Generon (Shanghai) |
| IL-22 IgG2-Fc | Acute GVHD | Phase I/II NCT02406651 | |
| ILV-094: anti-IL22 | HV | Phase I NCT00434746 | Pfizer |
| HV | Phase I NCT00447681 | ||
| Psoriasis | Phase I NCT00563524 | ||
| Atopic dermatitis | Phase II NCT01941537 | Rockefeller University | |
| Rheumatoid arthritis | Phase II NCT00883896 | Pfizer | |
| ILV-095: anti-IL22 | HV | Phase I NCT00822835 | Pfizer |
| HV | Phase I NCT00822484 | ||
| Psoriasis | Phase I NCT01010542 (terminated) | ||
| INGN 241 (Ad-mda-7) | Melanoma | Phase II NCT00116363 | Introgen Therapeutics |
Data source: clinicaltrials.gov.
GVHD, Graft-versus-host disease.